SCYNEXIS SCYX 深 滬
等待開盤 09-19 09:30:00 美东时间
1.02
+0.030
+3.03%
華盛通- 最 高1.0399
- 今 開0.985
- 成交量 40.04万股
- 最 低 0.985
- 昨 收 0.99
- 總市值 3980.07万
- 52周最高 1.62
- 市盈率 靜 --
- 換手率 1.03%
- 52周最低 0.66
- 委 比 -82.95%
- 總股本 3902.03万
- 歷史最高 150.00
- 量 比 1.22
- 振 幅 5.55%
- 歷史最低 0.66
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
SCYNEXIS announced six presentations on SCY-247 at the 12th TIMM Congress in Bilbao, Spain, highlighting its potential against resistant Candida and Aspergillus species. Data show SCY-247's strong in vitro activity against multidrug-resistant C. auris, including FKS1 mutants, and no cross-resistance to echinocandins. Preclinical studies demonstrate efficacy in murine models of C. auris and C. glabrata infections. The company plans to report Phase...
09-04 12:30
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
<p>SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company focused on developing innovative medicines to treat drug-resistant infections, announces that its senior leadership team will participate in the H.C. Wainwright 27th Annual Global Conference on Wednesday, September 10, 2025, in New York City. The event will include an in-person presentation from 10:30 a.m. to 11:00 a.m. ET and one-on-one meetings. SCYNEXIS is developing novel antifungal th...
08-25 12:00
SCYNEXIS Q2 EPS $(0.14) Beats $(0.19) Estimate, Sales $1.364M Beat $154.000K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 26.32 percent. This is a 53.33 percent increase over losses of $(0.30) per share from the same
08-14 04:34
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS reported Q2 2025 financial results, including revenue of $1.4M from the GSK License Agreement and a net loss of $6.9M. The company is progressing its Phase 3 MARIO study with GSK, triggering milestone payments despite disputes, and plans to transfer the BREXAFEMME NDA to GSK by year-end. SCYNEXIS anticipates Phase 1 data for SCY-247 in Q3 2025 and ended Q2 with $46.5M in cash, projecting a cash runway into Q4 2026. The company also saw a...
08-13 20:30
SCYNEXIS Holds Annual Meeting, Re-elects Directors
SCYNEXIS ( ($SCYX) ) just unveiled an update. On June 25, 2025, SCYNEXIS, Inc. ...
07-02 04:41
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
SCYNEXIS announced the resumption of patient dosing in its Phase 3 MARIO study for oral ibrexafungerp after the FDA lifted its clinical hold. This restart triggers a $10 million milestone payment from GSK, with an additional $20 million due in six months. Despite the milestone disputes between SCYNEXIS and GSK, patient enrollment has resumed, with nearly 25% of projected patients already enrolled. The study aims to evaluate ibrexafungerp as a ste...
05-28 12:30
SCYNEXIS Faces Challenges Amidst Antifungal Developments
SCYNEXIS Inc ( ($SCYX) ) has released its Q1 earnings. Here is a breakdown of t...
05-20 11:52
SCYNEXIS shares are trading lower following Q1 reported financial results.
SCYNEXIS shares are trading lower following Q1 reported financial results.
05-16 21:13
SCYNEXIS Q1 EPS $(0.11) Beats $(0.17) Estimate, Sales $257.00K Beat $205.50K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 35.29 percent. This is a 1200 percent decrease over earnings of $0.01 per share from the same
05-16 04:50
